Lipoproteins in Atherosclerosis Process

被引:15
作者
Arnao, Valentina [2 ,3 ]
Tuttolomondo, Antonino [1 ]
Daidone, Mario [1 ]
Pinto, Antonio [1 ]
机构
[1] Univ Palermo, Dept Hlth Promot Sci Maternal & Infant Care Inter, Internal Med & Stroke Care Ward, Palermo, Italy
[2] Univ Palermo, BioNeC Dipartimento BioMed Sperimentale & Neurosc, Palermo, Italy
[3] Univ Palermo, Biomed Dept Internal & Specialist Med DiBiMIS, PhD Sch Med Clin & Sci Comportamento, Palermo, Italy
关键词
Lipoproteins; oxidised; dysfunctional; atherogenisis; dyslipidemia; HDL-C; atherosclerosis; LOW-DENSITY-LIPOPROTEIN; PLATELET-ACTIVATING-FACTOR; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; APOLIPOPROTEIN-A-I; ENDOTHELIAL-CELL DYSFUNCTION; CYTOKINE-INDUCED EXPRESSION; SMOOTH-MUSCLE-CELLS; KAPPA-B ACTIVATION; C-REACTIVE PROTEIN; OXIDIZED PHOSPHOLIPIDS;
D O I
10.2174/0929867326666190516103953
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Dyslipidaemias is a recognized risk factor for atherosclerosis, however, new evidence brought to light by trials investigating therapies to enhance HDL-cholesterol have suggested an increased atherosclerotic risk when HDL-C is high. Results: Several studies highlight the central role in atherosclerotic disease of dysfunctional lipoproteins; oxidised LDL-cholesterol is an important feature, according to "oxidation hypothesis", of atherosclerotic lesion, however, there is today a growing interest for dysfunctional HDL-cholesterol. The target of our paper is to review the functions of modified and dysfunctional lipoproteins in atherogenesis. Conclusion: Taking into account the central role recognized to dysfunctional lipoproteins, measurements of functional features of lipoproteins, instead of conventional routine serum evaluation of lipoproteins, could offer a valid contribution in experimental studies as in clinical practice to stratify atherosclerotic risk.
引用
收藏
页码:1525 / 1543
页数:19
相关论文
共 175 条
[1]   CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY [J].
ANDERSON, KM ;
CASTELLI, WP ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16) :2176-2180
[2]  
[Anonymous], LIPPINCOTTS ILLUSTRA
[3]  
[Anonymous], 1993, HARPERS BIOCH
[4]  
[Anonymous], DISORDERS LIPID META
[5]  
[Anonymous], 1973, Form and function of phospholipids
[6]   The paradox of dysfunctional high-density lipoprotein [J].
Ansell, Benjamin J. ;
Fonarow, Gregg C. ;
Fogelman, Alan M. .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) :427-434
[7]   High-density lipoprotein: Is it always atheroprotective? [J].
Ansell B.J. ;
Fonarow G.C. ;
Fogelman A.M. .
Current Atherosclerosis Reports, 2006, 8 (5) :405-411
[8]   Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment [J].
Ansell, BJ ;
Navab, M ;
Hama, S ;
Kamranpour, N ;
Fonarow, G ;
Hough, G ;
Rahmani, S ;
Mottahedeh, R ;
Dave, R ;
Reddy, ST ;
Fogelman, AM .
CIRCULATION, 2003, 108 (22) :2751-2756
[9]  
Attie AD, 2001, J LIPID RES, V42, P1717
[10]   MODIFIED FORMS OF LOW-DENSITY LIPOPROTEIN AFFECT PLATELET-AGGREGATION INVITRO [J].
AVIRAM, M .
THROMBOSIS RESEARCH, 1989, 53 (06) :561-567